We are live on ! Find out more

Catalyst Pharmaceutical

CPRX

87 hedge funds and large institutions have $180M invested in Catalyst Pharmaceutical in 2015 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New

Increased

Maintained

Reduced

Closed

684% more call options, than puts

Call options by funds: $588K | Put options by funds: $75K

150% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 14

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

32% more funds holding

Funds holding: 66 → 87 (+21)

7% more capital invested

Capital invested by funds: $168M → $180M (+$11.3M)

Holders

Holders Change

+21

Holders Change %

+31.82%

% of All Funds

2.34%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$588K

Puts

$75K

Net Calls

+$513K

Net Calls Change

+$466K

Top Buyers

1	Federated Hermes Pittsburgh, Pennsylvania	+$10.3M
2	BFA BlackRock Fund Advisors San Francisco, California	+$7.14M
3	CCM Consonance Capital Management New York	+$2.66M
4	State Street Boston, Massachusetts	+$2.46M
5	BIT BlackRock Institutional Trust San Francisco, California	+$2.26M

Top Sellers

1	Point72 Asset Management Stamford, Connecticut	-$12.4M
2	Morgan Stanley New York	-$1.6M
3	PA Perceptive Advisors New York	-$1.39M
4	Susquehanna International Group Bala Cynwyd, Pennsylvania	-$1.26M
5	BBA Baker Bros. Advisors New York	-$916K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	BBA 1 Baker Bros. Advisors New York	$30.3M	-$916K	-229,770	-3%
2	CCM 2 Consonance Capital Management New York	$22.8M	+$2.66M	+668,015	+14%
3	3 Federated Hermes Pittsburgh, Pennsylvania	$18.8M	+$10.3M	+2,578,800	+130%
4	BC 4 Broadfin Capital New York	$17.3M	+$399K	+100,000	+2%
5	5 Point72 Asset Management Stamford, Connecticut	$14.3M	-$12.4M	-3,104,195	-47%
6	6 Franklin Resources San Mateo, California	$10.4M	–	–	–
7	7 Vanguard Group Malvern, Pennsylvania	$9.9M	+$672K	+168,549	+8%
8	BFA 8 BlackRock Fund Advisors San Francisco, California	$8.16M	+$7.14M	+1,792,219	+970%
9	CCA 9 Catalyst Capital Advisors Huntington, New York	$5.41M	+$937K	+235,000	+22%
10	SFM 10 Sphera Funds Management Tel Aviv, Israel	$4.96M	+$399K	+100,000	+9%
11	PA 11 Perceptive Advisors New York	$3.52M	-$1.39M	-348,800	-29%
12	BIT 12 BlackRock Institutional Trust San Francisco, California	$2.96M	+$2.26M	+566,044	+375%
13	13 State Street Boston, Massachusetts	$2.73M	+$2.46M	+616,859	+1,389%
14	PVI 14 Pura Vida Investments New York	$1.95M	+$120K	+30,000	+8%
15	15 Geode Capital Management Boston, Massachusetts	$1.68M	+$220K	+55,139	+16%
16	16 Allianz Asset Management Munich, Germany	$1.68M	+$373K	+93,496	+30%
17	17 Deutsche Bank Frankfurt Am Main Ge, Germany	$1.68M	+$651K	+163,408	+67%
18	HM 18 HealthCor Management New York	$1.59M	+$1.54M	+385,500	New
19	19 Morgan Stanley New York	$1.53M	-$1.6M	-400,218	-52%
20	20 Bank of New York Mellon New York	$1.28M	+$870K	+218,221	+237%
21	TI 21 Turner Investments Berwyn, Pennsylvania	$1.18M	+$1.14M	+286,370	New
22	BIM 22 BlackRock Investment Management Wilmington, Delaware	$1.11M	+$1.03M	+257,272	+2,153%
23	EI 23 EAM Investors Solana Beach, California	$954K	-$4.48K	-1,125	-0.5%
24	BA 24 BlackRock Advisors Wilmington, Delaware	$928K	+$856K	+214,754	+2,174%
25	CCI 25 Columbus Circle Investors	$861K	+$831K	+208,593	New

CPRX Hedge Fund Activity: Q2 2015 in Review

87 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2015, worth a combined $180M — up 6.7% from $168M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CPRX positions and 14 closed out — a net gain of 21 holders — while 24 added to existing stakes and 18 trimmed.

The largest buyer was Federated Hermes, adding an estimated $10.3M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.

87 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2015, up from 66 in Q1 2015.
Funds reported $180M of Catalyst Pharmaceutical stock for Q2 2015, up 6.7% quarter-over-quarter.
35 funds opened new Catalyst Pharmaceutical positions in Q2 2015 and 14 closed out, a net change of +21 holders.
The largest Catalyst Pharmaceutical buyer in Q2 2015 was Federated Hermes, an estimated $10.3M added.
The largest Catalyst Pharmaceutical seller in Q2 2015 was Point72 Asset Management, an estimated $12.4M sold.

Based on aggregated 13F filings for Q2 2015.

Catalyst Pharmaceutical CPRX